effect of supplement on appetite and glp-1

Conditions: Hunger

Summary: study summary the goal of this study is to understand whether a dietary supplement containing l-arginine, resveratrol, tart cherry, and vitamin c reduces hunger and increases the release of glp-1, a hormone associated with appetite suppression and improved glucose regulation. the study will also explore the metabolic effects of the supplement. main questions: 1. does the supplement reduce hunger more effectively than a placebo? 2. does it enhance glp-1 release in individuals with overweight or obesity? participants: * age: 18-60 years * body mass index (bmi): 25-40 kg/m² * total participants: 25 * must maintain usual eating and activity habits during the study. study design: * conditions tested: high-dose supplement, low-dose supplement, and placebo. * participants will undergo three separate 2-hour lab visits, each after fasting for 8 hours. * during each visit: * consume the assigned supplement or placebo. * eat a standardized meal after a 60-minute rest. * provide blood samples at eight time points to measure glp-1 and other metabolic markers. * rate hunger using a 7-point scale. benefits and risks: * benefits: participants may not directly benefit, but the findings could lead to new appetite-suppressing supplements that aid in weight loss. * risks: include discomfort from blood draws, possible gastrointestinal side effects from the supplement, and allergic reactions. measures are in place to minimize these risks, such as pre-screening for allergies and using trained personnel for blood collection. this study is triple-blinded, meaning neither the participants, researchers, nor analysts will know which condition is being tested during each visit. data collected will be anonymized to protect participant privacy.

study title: acute effect of supplement containing l-arginine on appetite suppression and glp-1 induction research objectives: the study aims to evaluate the effects of a dietary supplement containing l-arginine, resveratrol, tart cherry, and vitamin c on appetite suppression, glp-1 hormone release, and associated metabolic outcomes in individuals with overweight or obesity. background: glp-1 (glucagon-like peptide 1) plays a crucial role in regulating appetite and glucose homeostasis. condensed background information: the combination of the following ingredients is hypothesized to have a synergistic effect, promoting satiety and improving metabolic health: * l-arginine enhances glp-1 secretion, improving glucose tolerance and reducing appetite. * resveratrol inhibits dpp-iv, extending the activity of glp-1. * tart cherry supports metabolic regulation by enhancing nitric oxide availability and preventing arginine catabolism. * vitamin c acts as an antioxidant, supporting the efficacy of other components. participant details: * number of participants: 25 * eligibility criteria: * adults aged 18-60 years. * bmi between 25 and 40 kg/m². * must maintain current diet and physical activity levels. exclusion criteria: * significant weight change (\>5%) in the last three months. * medical conditions like uncontrolled diabetes, kidney disease, thyroid disorders, or autoimmune diseases. * current use of medications or supplements affecting weight or glp-1 levels. * pregnancy or lactation. study design: this is a randomized, triple-blinded, placebo-controlled study with three conditions: * high-dose supplement (\~10 g) * low-dose supplement (\~5 g) * placebo (\~5 g) each participant will experience all three conditions in random order. the timeline for the study involves: * pre-session: 8-hour fasting before each visit. * arrival at the lab (rickel building, rooms 256/259). * baseline blood sample collection. * administration of assigned supplement/placebo. * 60-minute rest period. * consumption of a standardized meal (bertolli chicken alfredo pasta bake) in isolation within a 30-minute window. * collection of additional blood samples at eight-time points * measurement of hunger using a 7-point scale. study procedures blood sampling: * 7 ml samples collected at each time point for metabolic analysis (e.g., glucose, insulin, glp-1). * total blood volume: 168 ml per participant across all sessions. * samples will be analyzed for metabolic markers in dr. ryan porter's lab. satiety measurement: participants will rate hunger levels at each blood draw using a scale from "extremely hungry" to "extremely full." meal intake: an ad libitum meal is provided to assess the impact of supplementation on food consumption. risks and mitigation * blood draw risks: bruising, pain, infection, or dizziness. managed by using trained personnel and aseptic techniques. * supplement risks: gastrointestinal discomfort and allergic reactions. addressed by pre-screening participants for allergies. emergency supplies will be available. * data privacy risks: all data will be anonymized and stored securely to prevent breaches. expected outcomes the study aims to determine: * if the supplement reduces hunger compared to a placebo. * if it enhances glp-1 release post-meal. * if it improves other metabolic parameters (e.g., glucose, lipid profiles). data handling: all data will be anonymized and securely stored. samples may be retained for up to 24 months for further research. statistical analysis: data analysis will use anova and tukey's post-hoc tests in spss, with significance set at p\<0.05. study impact: this research could contribute to developing effective nutritional interventions to support appetite regulation and weight management, benefiting individuals with obesity and/or metabolic disorders.

Eligibility criteria:
inclusion criteria: participants must meet all the following conditions to be eligible for the study: * age: 18-60 years old. * bmi (body mass index): between 25 and 40 kg/m². * diet and activity stability: willing to maintain current dietary and physical activity habits for the duration of the study. exclusion criteria: participants will be excluded from the study if any of the following conditions apply: * recent weight change: lost or gained more than 5% of body weight in the last 3 months. * pregnancy or lactation: pregnant or breastfeeding women. * medical conditions: * kidney disease (chronic kidney disease or end-stage renal disease). * herpes simplex. * uncontrolled diabetes (hba1c \>7%). * thyroid disorders or taking thyroid medications. * type 1 diabetes. * cushing syndrome. * cirrhosis or hepatitis. * chronic obstructive pulmonary disease (copd). * dementias. * active autoimmune diseases (e.g., lupus, rheumatoid arthritis). * crohn's disease or ulcerative colitis. * celiac disease. * allergies or sensitivities: * known allergies to any components of the supplement or standardized meal. * medications: currently taking any of the following: * supplements or medications for weight loss. * antihypertensive, antidiabetic, or antihyperlipidemic medications. * erectile dysfunction medications. * blood thinners (e.g., aspirin, warfarin). * medications containing nitric oxide or nitroglycerin. * drugs affecting glp-1 levels, such as glp-1 receptor agonists, insulin, certain antidepressants, or corticosteroids. * substance use: evidence of illegal drug use, including marijuana. * participation in other studies: enrollment in another clinical trial that could interfere with the study outcomes.

Keywords: hunger glp-1 satiety supplement